Evaluating in Vivo Efficacy – Toxicity Profile of TEG001 in Humanized Mice Xenografts Against Primary Human AML Disease and Healthy Hematopoietic Cells
Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-019-0558-4
Full Text
Open PDFAbstract
Available in full text
Date
March 12, 2019
Authors
Publisher
BMJ